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Summary:
Schizophrenia and anorexia nervosa were recently added to the list of conditions for which 
whole genome sequencing might be indicated as part of the 100,000 Genomes Project, 
reflecting the remarkable recent progress in findings emerging from psychiatric genetics 
research.  Genetic testing methods may offer increased opportunities for diagnosis and 
estimation of familial risk and could have implications for management and treatment 
options.  They also present ethical and philosophical questions about the role of testing and 
storage of genetic information. Mental health professionals will need to have a good 
understanding of this area in order for patients to fully realise the benefits of these advances.
At the end of September 2018 recruitment finished for the 100,000 Genomes Project, a pilot 
diagnostic service implemented by the UK National Health Service (NHS) which offered 
whole genome sequencing to patients with rare diseases or cancer through a separate 
company established by the UK government called Genomics England. Eligible rare diseases 




included mental disorders such as intellectual disability and early onset dementia and, 
following new research findings, schizophrenia and anorexia nervosa were added from 
January 2018. This addition reflected the real and remarkable progress that has been made in 
identifying genetic risk factors for these diseases. For schizophrenia, it has been shown that 
certain copy number variants (CNVs) and sequence variants that damage a small number of 
genes have major effects on risk; additionally some variants already known to cause 
intellectual disability may have schizophrenia as a phenotype (1,2). For anorexia nervosa, a 
recent genome wide association study has shown that genetic risk is shared not only with 
schizophrenia but also with risks associated with markers of metabolic disorders such as 
high-density lipoprotein cholesterol and body mass index (3). For both diagnoses, inclusion 
criteria were specified with the aim of making it more likely that an identifiable genetic cause 
would be found – for schizophrenia that additional features such as early onset, neurological 
signs or dysmorphism were present; for anorexia that the condition was severe and familial.
Although recruitment to the 100,000 Genomes Project has now finished, the results from 
sequencing these subjects are awaited and these results will inform decisions regarding which 
genetic tests which will be provided by the newly established NHS Genomic Medicine 
Service. These tests are listed in National Genomic Test Directories and, of relevance to 
psychiatrists, the first versions of these already provide for microarray testing for autism or 
mild intellectual disability and whole genome sequencing for more severe forms of 
intellectual disability and for dysmorphism syndromes thought likely to be monogenic 
(https://www.england.nhs.uk/publication/national-genomic-test-directories). It is expected 
that further indications for testing, such as microarray testing for schizophrenia CNVs, will 
be added as new evidence is evaluated. 
With the current state of knowledge, the proportion of patients with mental illness in whom a 
“probable genetic diagnosis” will be made is likely to be low. A recent study found that it 
was possible to detect a pathogenic CNV in 2.8% of participants with schizophrenia without 
intellectual disability , though this figure rose to 24.2% with co-morbid intellectual disability 
(4). In the future, when further genetic risk variants are characterised, it will be possible to re-
examine stored DNA sequence and identify the patients carrying them and make 
retrospective diagnoses. Thus, it is reasonable to expect that over time the diagnostic yield 
will increase. Even for those patients in whom a diagnosis relevant to the psychiatric 
condition cannot be made there may still be benefits from “secondary findings” of genomic 




sequencing, consisting of the detection of important genetic variants having actionable 
medical consequences such as increasing risk of cancer. Again, as genetic knowledge 
increases it is likely that the overall benefit from such findings will also grow.  However, it 
will be important that patients are aware of such possible outcomes and that appropriate 
processes of gaining valid consent are developed.
Although the future looks promising, it would currently be over-optimistic to expect that 
identification of specific genetic variants would at this stage guide, for example, choices 
around which antipsychotic to use. However concrete benefit could certainly come in terms 
of a clearer understanding of familial risk. Where a de novo variant is identified one may be 
able to reassure relatives that nobody else in the family is at increased risk of developing the 
illness. Alternatively, if a variant is inherited then it will become possible to provide clear 
information about risk to patients and their families and offer genetic testing to, for example, 
siblings. Sometimes a variant may be associated with other potential health problems, for 
example, a finding of a 22q11 deletion (DiGeorge syndrome) could lead to screening for 
cardiac abnormalities and registration with the National Congenital Anomaly and Rare 
Disease Registration Service.
The more important benefits of genetic testing for psychiatric disorders may be less tangible. 
For some patients, presently a minority, a clear genetic diagnosis will be made that allows the 
patient and those around them to ascribe their illness to a specific, physical cause. Even if this 
might not have material effects on the management plan we argue that, for some patients, 
there is an intrinsic value in “having a diagnosis”. For some physical illnesses the diagnosis 
can have little in the way of practical implications but may still provide an explanation and 
validation of the sick role. In the context of psychiatric illness, where lack of insight and poor 
compliance can be problematic, there may be a special benefit in being able to provide the 
patient and those around them with information about a concrete medical explanation which 
has led them to experience frightening symptoms. Potentially, ascribing illness to a more 
clearly defined physical cause could reduce stigma. Here, we see that the attempt to provide a 
diagnosis represents a manifestation of “parity of esteem” between mental and physical 
illness. People with mental illness are entitled to all appropriate and available tests to 
investigate the cause of their condition, just as those presenting with a physical health 
condition would be. We might anticipate that when a clear molecular genetic diagnosis can 
be made for a condition such as schizophrenia, which often attracts diagnostic uncertainty, 




then this may lead to improved engagement and shared decision making. This may extend to 
refining the care process and precision in prescribing effective medication. Arguably, even 
when no genetic diagnosis is achieved then the very act of testing can send a clear message 
that the clinician believes that biological factors are important, that the illness is “real” and 
that devising a management plan which includes medical treatment is as appropriate as it 
would be for a “physical” illness such as asthma or diabetes. Although it is argued by some 
that a biological causal explanation could actually increase stigma, ultimately having clear 
evidence for a particular aetiology for certain patients might prove preferable to simply 
having a variety of optional explanatory models on offer. 
Till now, few psychiatric patients have been offered genetic testing or been given much 
information about genetic risks. Clinicians themselves may have little awareness that for 
some patients such testing can give them helpful explanations about causation, and may also 
support them to manage other health issues. However this situation will inevitably change, as 
indeed is the case for a range of physical diseases. Such change will necessitate making use 
of innovative techniques for data gathering, storage and sharing between primary and 
secondary care. Thus this also bodes well for the integration of care systems to improve 
physical and mental health.
There are ethical and philosophical issues that need exploration and further research is 
needed to explore the role for testing and appropriate forms of information sharing. How will 
these new practices be implemented in culturally diverse settings, with contrasting levels of 
resource, health literacy and access to basic care systems? A study of the effects of genetic 
counselling for severe mental illness showed benefits in terms of increased knowledge but 
not stigma or perceived control (5). As genetic testing is rolled out it will be important to 
formally evaluate outcomes so that its advantages and disadvantages can be properly 
characterised. It will also be helpful to assess attitudes of patients and clinicians to testing, 
particularly when these may act as potential barriers, or indeed involve patients in the design 
and development of genetic testing pathways. Will patients have concerns about their DNA 
sequence being stored and contributing to a wider understanding of how genetic variation 
impacts on health? Will clinicians feel confident about the level of information they are 
providing and with justifications for referral to clinical genetics services? Do they have 
concerns about their ability to work alongside clinical genetics services in assisting the 




patient and those around them to correctly understand, interpret and share the results of 
testing? Will the attribution of mental illness to a genetic cause reduce stigma or increase it? 
How will genetic information be routinely incorporated into the care plan approach and 
electronic data with all the concerns around information governance and commercial 
exploitation? A robust programme of research will be required to address these questions.
Psychiatrists in the NHS now have an opportunity to take advantage of the latest medical 
technology and refer appropriate patients for genetic testing. In doing so, they can send the 
clear message that they believe that psychiatric disorders can at least sometimes be due to 
genetic abnormalities and that there is value in identifying them. Patients have the right to be 
given the opportunity to access the best science, technology and clinical information systems, 
in order to understand as much as is currently possible about the nature of their own health 
problems. Although clinical genetics services will have a role, it seems certain that both 
medical and non-medical mental health professionals will need to improve their 
understanding of medical genetics and the ethical considerations around sharing genetic 
information. Training in this area is an issue which the Royal College of Psychiatrists should 
address as a high priority if psychiatric patients are to fully share the benefits of scientific 
progress.
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